Granite Bio has secured $100 million in funding, indicating strong investor confidence and market potential for its antibody treatments.
Company Description
Granite Bio is a Swiss-based immunology company focused on developing new antibody treatments targeting various autoimmune diseases. The company aims to address fundamental disease drivers at their source with innovative therapies.